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BACKGROUND
The successful treatment of intraabdominal infection requires a combination of ana-
tomical source control and antibiotics. The appropriate duration of antimicrobial 
therapy remains unclear.
METHODS
We randomly assigned 518 patients with complicated intraabdominal infection and 
adequate source control to receive antibiotics until 2 days after the resolution of 
fever, leukocytosis, and ileus, with a maximum of 10 days of therapy (control group), 
or to receive a fixed course of antibiotics (experimental group) for 4±1 calendar days. 
The primary outcome was a composite of surgical-site infection, recurrent intraab-
dominal infection, or death within 30 days after the index source-control proce-
dure, according to treatment group. Secondary outcomes included the duration of 
therapy and rates of subsequent infections.
RESULTS
Surgical-site infection, recurrent intraabdominal infection, or death occurred in 
56 of 257 patients in the experimental group (21.8%), as compared with 58 of 
260 patients in the control group (22.3%) (absolute difference, −0.5 percentage 
point; 95% confidence interval [CI], −7.0 to 8.0; P = 0.92). The median duration of 
antibiotic therapy was 4.0 days (interquartile range, 4.0 to 5.0) in the experimental 
group, as compared with 8.0 days (interquartile range, 5.0 to 10.0) in the control 
group (absolute difference, −4.0 days; 95% CI, −4.7 to −3.3; P<0.001). No signifi-
cant between-group differences were found in the individual rates of the compo-
nents of the primary outcome or in other secondary outcomes.
CONCLUSIONS
In patients with intraabdominal infections who had undergone an adequate source-
control procedure, the outcomes after fixed-duration antibiotic therapy (approxi-
mately 4 days) were similar to those after a longer course of antibiotics (ap-
proximately 8 days) that extended until after the resolution of physiological 
abnormalities. (Funded by the National Institutes of Health; STOP-IT ClinicalTrials 
.gov number, NCT00657566.)
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Complicated intraabdominal infec-tion continues to be a common problem worldwide. Approximately 300,000 cases 
of appendicitis occur each year in the United States,1 
and at least twice that many cases of non-appen-
diceal infection require management.2 Morbidity 
ranges from 5% among patients evaluated in broad 
observational studies2-4 to close to 50% in some 
cohorts, such as the elderly or critically ill.5,6 De-
spite the diversity of specific processes in these 
infections, the basic tenets of management are 
similar: resuscitate patients who have the systemic 
inflammatory response syndrome (SIRS), control 
the source of contamination, remove most of the 
infected or necrotic material, and administer anti-
microbial agents to eradicate residual pathogens.7,8
Antimicrobial therapy for the management of 
intraabdominal infections continues to evolve. 
Published guidelines include recommendations 
for appropriate antimicrobial agents on the basis 
of high-quality evidence.7,8 The appropriate dura-
tion of therapy, however, remains unclear. Tradi-
tionally, practitioners have treated patients until 
all evidence of SIRS has resolved, typically for 7 to 
14 days. More recently, it has been suggested that 
with adequate source control, a shorter course of 
3 to 5 days should suffice for cure9 and could de-
crease the risk of antimicrobial resistance. Cur-
rently used guidelines, including those published 
jointly by the Surgical Infection Society (SIS) and 
the Infectious Diseases Society of America (IDSA), 
recommend a treatment course of 4 to 7 days, de-
pending on the clinical response.7,8
Despite these recommendations, observational 
studies show that therapy is typically administered 
for 10 to 14 days.4,10,11 One reason that shortening 
therapy has been difficult is the 20% rate of clini-
cally significant infectious complications after 
treatment.3 These subsequent complications, how-
ever, are often due to progression of the original 
disease or inadequate original source control and 
may not be preventable with antimicrobial therapy 
alone.
We conducted the randomized Study to Opti-
mize Peritoneal Infection Therapy (STOP-IT) trial 
to compare two strategies guiding the duration 
of antimicrobial therapy for the management of 
complicated intraabdominal infection. We hypoth-
esized that the administration of fixed-duration 
antibiotic therapy (4 days) after source control 
would lead to equivalent outcomes and a shorter 
duration of therapy as compared with the tradi-
tional strategy of administration of antibiotics 
until 2 days after the resolution of the physiolog-
ical abnormalities related to SIRS.
Me thods
Study Population
Patients were eligible for enrollment in the study 
if they were 16 years of age or older; if they pre-
sented with a complicated intraabdominal infec-
tion with either fever (temperature ≥38.0°C), leu-
kocytosis (≥11,000 peripheral white cells per cubic 
millimeter), or gastrointestinal dysfunction due 
to peritonitis precluding intake of more than half 
their normal diet; and if they had undergone an 
intervention to achieve source control.
Source control, defined as procedures that 
eliminate infectious foci, control factors that pro-
mote ongoing infection, and correct or control 
anatomical derangements to restore normal phys-
iological function, is critical to the management 
of any infection.12 The adequacy of source control 
was confirmed by the local investigator and the 
principal investigator of the overall study (see the 
full protocol, available with the full text of this 
article at NEJM.org).
Study Design and Oversight
In this investigator-initiated, open-label, multi-
center trial, we randomly assigned participants in 
a 1:1 ratio to receive 4 full days of antimicrobial 
therapy after their index source-control procedure 
(experimental group) or to receive antimicrobial 
therapy until 2 days after the resolution of the 
physiological abnormalities related to SIRS (con-
trol group). This resolution was defined as a 
body temperature of less than 38.0°C for 1 entire 
calendar day, normalization of the peripheral 
white-cell count to less than 11,000 per cubic 
millimeter, and the patient’s ability to consume 
more than half of his or her regular diet without 
adverse effects.
All the patients or their legal surrogates 
provided written informed consent. The specific 
choice of antimicrobial agents was not dictated 
by the protocol but rather was considered to be 
acceptable if it was consistent with published 
SIS–IDSA guidelines.7,8
Randomization was performed with the use 
of a Web-based data system managed by Merge 
Healthcare, an independent contract research or-
ganization paid by the sponsor. Each study site 
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used a unique randomization sequence. Only 20 
patients with appendiceal disease were permitted 
in each sequential block of 200 randomly assigned 
patients. Patients were enrolled at 23 sites through-
out the United States and Canada, and the study 
was coordinated through the SIS and managed 
by the University of Virginia team. The protocol 
was approved by the institutional review board at 
each site. All the authors vouch for the accuracy 
and completeness of the data, the analyses re-
ported here, and the fidelity of the study to the 
protocol.
Duration of Therapy and Adherence  
to the Protocol
After randomization, patients were followed to 
assess their clinical course and adherence to the 
protocol. In the control group, adherence to the 
protocol was defined as the receipt of appropri-
ate antimicrobial agents until 2±1 calendar days 
after the first day that the patient had a maxi-
mum temperature of less than 38.0°C for 1 whole 
calendar day, less than 11,000 peripheral white 
cells per cubic millimeter, and the ability to 
meet more than half their nutritional needs en-
terally. A maximum of 10 days of therapy was 
allowed for treatment of the initial intraabdomi-
nal infection.
In the experimental group, adherence to the 
protocol was defined as the receipt of effective 
antimicrobial agents for 4±1 calendar days after 
the index source-control procedure. Patients were 
followed for 30 days after the initial source-con-
trol procedure and assessed for infectious com-
plications, use of antimicrobial therapy, and death 
from any cause. Patients hospitalized for more 
than 30 days were followed to determine hospi-
tal length of stay. A resistant pathogen was de-
fined as methicillin-resistant Staphylococcus aureus, 
any vancomycin-resistant enterococcus species, 
or a gram-negative organism that was resistant 
to all members of a major class of antimicrobial 
agents.
Statistical Analysis
The primary analysis compared the proportion of 
patients in each group in whom a surgical-site in-
fection or recurrent intraabdominal infection de-
veloped or in whom death occurred within 30 days 
after the index source-control procedure. Analy-
ses were performed with the use of the chi-square 
test with Yates’ correction, Student’s t-test, or Wil-
coxon signed-rank test, where applicable, in the 
intention-to-treat population, which consisted of 
all patients who provided consent and underwent 
randomization. Kaplan–Meier curves for time to 
an event were constructed and compared with 
the use of the log-rank test.
Secondary analyses assessed the duration of 
antimicrobial therapy for the index infection, 
overall exposure to antimicrobial agents, rates of 
subsequent extraabdominal infection, and ad-
herence to the protocol. Prespecified subgroups 
for analysis included patients with an Acute Physi-
ology and Chronic Health Evaluation (APACHE) II 
score of 10 or higher (on a scale of 0 to 71, with 
higher scores indicating an increased risk of 
death), patients with a health care–associated 
infection, patients with an appendiceal source of 
index infection and those with a non-appendi-
ceal source of index infection, and patients with 
an index infection treated by surgical drainage 
and those whose index infection was treated by 
percutaneous drainage. Multivariate logistic re-
gression was performed to determine associa-
tions with the composite outcome, including key 
demographic variables and treatment-group as-
signments.
According to the original sample-size calcula-
tion to define equivalence between the two groups, 
we calculated that a sample of 505 patients per 
group would be required to give the study 90% 
power to detect a 10% difference in complication 
rates, assuming a 30% complication rate among 
controls and assuming a dropout rate of 10%, at 
an alpha level of 0.05. After the first interim 
analysis showed nearly identical outcomes in the 
two cohorts, a competitive renewal request for 
continued support to reach the targeted enrollment 
levels was not funded owing largely to a concern 
for futility.
R esult s
Patient Characteristics and Index Infections
From August 2008 through August 2013, a total 
of 518 patients underwent randomization. One 
patient withdrew consent after randomization. 
Thirty-day follow-up was completed in 99.8% of 
the patients (Fig. 1).
The mean (±SE) age of the patients was 
52.2±1.0 years (range, 16 to 88); most of the pa-
tients were male, and the composition of racial 
and ethnic groups was similar in the two groups. 
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The mean APACHE II score for the index infec-
tion was 10.1±0.3 (range, 0 to 29), the most com-
mon origin of the infection was the colon or rec-
tum, and one third of the infections were treated 
with a percutaneous procedure (Table 1). Com-
plete demographic data are provided in Table S1 
in the Supplementary Appendix, available at NEJM 
.org. There were no differences between the two 
study groups, at a significance level of less than 
0.05, with respect to any demographic variable.
Adherence to the Protocol
A total of 211 of 258 patients in the experimental 
group (81.8%), as compared with 189 of 260 pa-
tients in the control group (72.7%), ultimately re-
ceived antimicrobial therapy for the protocol-
specified duration (P = 0.02) (Fig. 1). In the control 
group, 10 patients received therapy for too few 
days, including 7 patients who continued to have 
an elevated white-cell count and 4 patients who 
had ongoing gastrointestinal dysfunction when 
therapy was discontinued. Among the other pa-
tients who did not receive the assigned therapy, 
26 received therapy for less than 10 days (but lon-
ger than required according to their physiological 
findings) and 35 received therapy for more than 
10 days. In some patients in the control group, 
the initial course of antimicrobial therapy was 
extended owing to a second infection, and they 
were considered to be in violation of the proto-
col; 6 of these patients had a surgical-site infec-
tion, 8 had a recurrent intraabdominal infection, 
and 1 had an infectious disease owing to extra-
abdominal infection.
In the experimental group, all 47 patients who 
did not adhere to the protocol received a treat-
Figure 1. Enrollment, Randomization, and Treatment.
All enrolled patients had complicated intraabdominal infection and adequate source control. The control group con-
sisted of patients who received antibiotics until 2 days after resolution of fever, leukocytosis, and ileus, with a maxi-
mum of 10 days of therapy, and the experimental group received a fixed course of antibiotics for 4±1 calendar days.
518 Patients were enrolled and underwent randomization
260 Were assigned to control group
189 Received assigned intervention
71 Did not receive assigned intervention
26 Received more treatment than required
on basis of physiological findings, but
for <10 days total
35 Received treatment for >10 days
6 Had new surgical-site infection
8 Had recurrent intraabdominal infection
1 Had infectious disease owing to extra-
abdominal infection
20 Had no identifiable reason to receive
>10 days of treatment
10 Received therapy for too few days for
no identifiable reason
258 Were assigned to experimental group
211 Received assigned intervention
47 Did not receive assigned intervention
owing to >5 days of treatment
16 Had ongoing elevated white-cell count
12 Had gastrointestinal dysfunction
6 Had no identifiable reason to receive
>5 days of treatment
2 Had persistent fever
2 Had new surgical-site infection
7 Had recurrent intraabdominal infection
1 Had extraabdominal infection
1 Withdrew consent after receiving antibiotic
therapy
260 Were included in 30-day follow-up 257 Were included in 30-day follow-up
260 Were included in primary intention-to-treat
analysis
189 Were included in evaluation of patients who
adhered to study protocol
257 Were included in primary intention-to-treat
analysis
211 Were included in evaluation of patients who
adhered to study protocol
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ment course that was longer than the duration 
specified in the protocol. Of these patients, 16 had 
an ongoing elevated white-cell count, 2 had per-
sistent fever, and 12 continued to have gastroin-
testinal dysfunction that prevented enteral intake. 
A new infection leading to extension of antimi-
crobial therapy for more than 4 days occurred in 
10 patients, including 2 with a surgical-site infec-
tion, 7 with a recurrent intraabdominal infection, 
and 1 with an extraabdominal infection. Two pa-
tients with recurrent intraabdominal infection also 
had a persistently elevated white-cell count.
Primary and Major Secondary Outcomes
The composite primary end point of surgical-site 
infection, recurrent intraabdominal infection, or 
death occurred in 56 of 257 patients in the experi-
mental group (21.8%), as compared with 58 of 260 
patients in the control group (22.3%) (absolute 
difference, −0.5 percentage point, 95% confidence 
interval [CI], −7.0 to 8.0; P = 0.92) (Table 2). Ka-
plan–Meier analysis showed no significant be-
tween-group difference in the time to the com-
posite primary outcome (Fig. 2).
No significant between-group differences were 
seen in the rates of the individual primary-end-
point components of surgical-site infection (abso-
lute difference, −2.2 percentage points; 95% CI, 
−2.4 to 7.0; P = 0.43), recurrent intraabdominal in-
fection (absolute difference, 1.8 percentage points; 
95% CI, −4.5 to 7.8; P = 0.67), and death (absolute 
difference, 0.4 percentage point; 95% CI, −1.7 to 
2.7; P = 0.99). Diagnosis of surgical-site infection 
and recurrent intraabdominal infection, but not 
death, occurred significantly later in the control 
group than in the experimental group (Table 2). 
Death occurred in 5 of the 518 patients in the 
two groups combined (1.0%, 2 patients in the 
control group and 3 patients in the experimental 
group) at a mean of 18.7±0.4 days after the index 
source-control procedure. All the deaths were 
judged by the site principal investigator and the 
study principal investigator to be related to under-
lying coexisting diseases (principally cancer and 
cardiovascular disease) and not to the initial in-
traabdominal infection.
The median duration of antimicrobial treat-
ment for the index intraabdominal infection was 
4.0 days (interquartile range, 4.0 to 5.0) in the 
experimental group, as compared with 8.0 days 
(interquartile range, 5.0 to 10.0) in the control 
group (absolute difference, −4.0 days; 95% CI, 
−4.7 to −3.3; P<0.001). There were significantly 
fewer median antimicrobial-free days at 30 days 
(including all antimicrobial therapy) in the con-
trol group than in the experimental group. No 
significant between-group differences were found 
with respect to the rates of extraabdominal infec-
tion, Clostridium difficile infection, or secondary in-
fections with resistant pathogens (Table 2).
Outcomes in Prespecified Subgroups
The occurrence of the primary composite outcome 
was similar in the two study groups in all pre-
specified subgroups, including patients who were 
Variable
Control 
Group 
(N = 260)
Experimental 
Group 
(N = 258)
Age — yr 52.2±1.0 52.2±1.0
Male sex — no. (%) 145 (55.8) 144 (55.8)
Race or ethnic group — no. (%)†
White 208 (80.0) 196 (76.0)
Black 43 (16.5) 51 (19.8)
Asian 5 (1.9) 6 (2.3)
American Indian or Alaskan Native 2 (0.8) 1 (0.4)
Hispanic — no. (%) 20 (7.7) 15 (5.8)
Other 2 (0.8) 4 (1.6)
Characteristics of index infection
APACHE II score‡ 9.9±0.4 10.3±0.4
Maximum white-cell count — per mm3 15,600±0.4 17,100±0.7
Maximum body temperature — °C 37.8±0.1 37.7±0.1
Organ of origin — no. (%)
Colon or rectum 80 (30.8) 97 (37.6)
Appendix 34 (13.1) 39 (15.1)
Small bowel 31 (11.9) 42 (16.3)
Source-control procedure — no. (%)
Percutaneous drainage 86 (33.1) 86 (33.3)
Resection and anastomosis or closure 69 (26.5) 64 (24.8)
Surgical drainage only 55 (21.2) 54 (20.9)
Resection and proximal diversion 27 (10.4) 37 (14.3)
Simple closure 20 (7.7) 12 (4.7)
Surgical drainage and diversion 3 (1.2) 4 (1.6)
*  Plus–minus values are means ±SE. There were no significant differences be-
tween the groups (P<0.05).
†  Race and ethnic groups were reported by the patient or surrogate.
‡  Acute Physiology and Chronic Health Evaluation (APACHE) II scores range 
from 0 to 71, with higher scores indicating an increased risk of death.
Table 1. Baseline Demographic and Clinical Characteristics, According to 
Study Group.*
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treated per protocol (33 of 189 patients in the 
control group [17.5%] and 37 of 211 patients in 
the experimental group [17.5%]; absolute differ-
ence, 0.1 percentage point; 95% CI, −7.4 to 7.6; 
P = 0.72) (Fig. 3, and Table S2 in the Supplemen-
tary Appendix). Differences in the duration of 
therapy among patients in all subgroups were 
similar to those seen in the intention-to-treat 
analysis, with the exception of the subgroup of 
patients who were not treated according to the 
Variable
Control 
Group 
(N = 260)
Experimental 
Group 
(N = 257) P Value
Primary outcome: surgical-site infection, recurrent intraabdominal 
infection, or death — no. (%)
58 (22.3) 56 (21.8) 0.92
Surgical-site infection 23 (8.8) 17 (6.6) 0.43
Recurrent intraabdominal infection 36 (13.8) 40 (15.6) 0.67
Death 2 (0.8) 3 (1.2) 0.99
Time to event — no. of days after index source-control procedure
Diagnosis of surgical-site infection 15.1±0.6 8.8±0.4 <0.001
Diagnosis of recurrent intraabdominal infection 15.1±0.5 10.8±0.4 <0.001
Death 19.0±1.0 18.5±0.5 0.66
Secondary outcome
Surgical-site infection or recurrent intraabdominal infection with  
resistant pathogen — no. (%)
9 (3.5) 6 (2.3) 0.62
Site of extraabdominal infection — no. (%)
Any site† 13 (5.0) 23 (8.9) 0.11
Urine 10 (3.8) 13 (5.1) 0.65
Blood 3 (1.2) 5 (1.9) 0.71
Lung 3 (1.2) 3 (1.2) 0.99
Area of skin other than surgical site 1 (0.4) 4 (1.6) 0.36
Vascular catheter 0 (0) 2 (0.8) 0.47
Clostridium difficile infection — no. (%) 3 (1.2) 5 (1.9) 0.71
Extraabdominal infection with resistant pathogen — no. (%) 6 (2.3) 2 (0.8) 0.29
Duration of outcome — days
Antimicrobial therapy for index infection <0.001
Median 8 4
Interquartile range 5–10 4–5
Antimicrobial-free days at 30 days <0.001
Median 21 25
Interquartile range 18–25 21–26
Hospitalization after index procedure 0.48
Median 7 7
Interquartile range 4–11 4–11
Hospital-free days at 30 days 0.22
Median 23 22
Interquartile range 18–26 16–26
*  Plus–minus values are means ±SE.
†  Some patients had extraabdominal infections at more than one site.
Table 2. Primary and Major Secondary Outcomes.*
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protocol, for whom the median duration was 11 
days in both groups. Results of the logistic- 
regression analysis are provided in Table S3 in 
the Supplementary Appendix; there was no sig-
nificant interaction between treatment groups 
and the primary composite outcome.
Discussion
In this randomized study involving patients with 
complicated intraabdominal infections, a fixed 
duration of 4 days of antibiotic treatment re-
sulted in outcomes that were similar to those of 
a traditional, longer course that was based on 
resolution of physiological abnormalities, and 
the shorter course was associated with signifi-
cantly fewer days of antibiotic exposure. These 
data provide support for the concept that after 
an adequate source-control procedure, the ben-
eficial effects of systemic antimicrobial therapy 
are limited to the first few days after interven-
tion. In addition, it might be argued that the 
delay in manifestation of infectious complica-
tions in the control group was itself an adverse 
outcome, since the time to recognition of these 
events and, therefore, the overall time to resolu-
tion of all infections was prolonged.
Traditionally, physicians have administered 
antimicrobial therapy in patients who have in-
traabdominal infections until clinical and labo-
ratory evidence suggests that the infection has 
resolved. They reasoned that ongoing sepsis was 
indicative of ongoing replication of pathogens. 
More recent experimental data, however, suggest 
that a prolonged SIRS may be more a reflection 
of host immune activity than an indication of 
the presence of viable microorganisms.13-15 As 
such, efforts have begun to shorten the duration 
of antimicrobial therapy in the presence of tra-
ditional markers of sepsis. These efforts have 
already been successful in other severe infec-
tions such as ventilator-associated pneumonia.16
Currently, the average duration of antibiotic 
therapy for intraabdominal infection is 10 to 14 
days.4,10,11 The results of smaller studies of the 
effect of an abbreviated course of antimicrobial 
therapy have been published. Schein et al. reported 
on an uncontrolled study in which 23 consecutive 
patients with diffuse peritonitis were assigned 
to receive 3 to 5 days of antibiotics.9 Infections 
developed in 22% of these patients; these rates 
were similar to those seen in a historical cohort. 
Basoli et al., who randomly assigned 90 patients 
with mild-to-moderate intraabdominal infection 
to either 3 days or 5 or more days of ertapenem 
therapy, found no between-group difference in 
infectious outcomes.17 Those findings, however, 
are not generalizable to the majority of patients 
with intraabdominal infection, since half the pa-
tients had appendiceal disease and the overall rate 
of infectious complications was less than 10%. As 
compared with these studies, the STOP-IT trial 
had several advantages, including a larger sample 
size, randomized design, and enrollment of pa-
tients with a broader range of severity of illness.
The rate of infectious complications was more 
than 20% in both groups of our study, and most 
of these complications were recurrent intraab-
dominal infections. Given the large difference in 
the number of days of treatment in the two study 
groups, neither shortening nor lengthening the 
duration of antimicrobial therapy appears likely 
to affect infectious outcomes. Truly clinically sig-
nificant improvement in the management of this 
disease, therefore, probably awaits more effective 
technical or immune response–modifying inter-
ventions. However, the observed mortality in our 
study was only 1%; this is better than anticipat-
ed among patients with a mean APACHE II score 
Figure 2. Kaplan–Meier Time-to-Event Curves for the Composite Primary 
Outcome, According to Treatment Group.
The composite primary outcome was surgical-site infection, recurrent in-
traabdominal infection, or death.
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of 10 and is perhaps related to the reduction in 
mortality from many serious infections noted 
after the initiation of the Surviving Sepsis Cam-
paign.18
Strengths of the trial include the inclusion of 
23 centers and the similarity in outcomes between 
the control group and the experimental group in a 
wide variety of important, prespecified subgroups. 
For example, although rates of complications 
differed according to the severity of illness and 
the method of source control (percutaneous vs. 
surgical drainage), the effect size was similar in 
the two study groups. These findings suggest that 
the results may well be generalizable across a 
wide array of patient populations, care settings, 
and interventions, as long as adequate source 
control is first achieved.
Several limitations to the interpretation of 
these data are worth noting. First, patients without 
adequate source control were excluded, and only a 
small number of patients with immunosuppres-
sion were included; it remains unclear whether 
these populations would benefit from a longer 
duration of therapy. Second, the rate of nonad-
herence to the protocol was moderately high, 
including 18% of patients in the experimental 
group; this created bias toward the null hypoth-
esis of no difference in therapy, though the fact 
that the per-protocol population had similar com-
plication rates between the experimental and 
control groups is reassuring. Finally, the original 
calculated sample size to assert equivalence be-
tween groups was not achieved and proof of 
equivalence cannot be claimed, although the 95% 
confidence interval for the difference in event rates 
was −7.0 to 8.0 and provides encouraging evidence 
that the true difference is less than 10%. In other 
words, the null hypothesis of equal efficacy can-
not be rejected.
In conclusion, outcomes in patients with in-
traabdominal infections who have undergone a 
successful source-control procedure and receive 
a fixed, 4-day course of antimicrobial therapy ap-
pear to be generally similar to outcomes in pa-
Figure 3. Primary Composite Outcome in Key Subgroups.
The median proportions of patients with the composite outcome are shown. I bars indicate the interquartile range.
0.2 0.3 0.50.4
Adhered to protocol
Control
Experimental
Did not adhere to protocol
Control
Experimental
APACHE II score ≥10
Control
Experimental
Health care–associated infection
Control
Experimental
Percutaneous drainage
Control
Experimental
Surgical drainage
Control
Experimental
Appendiceal source
Control
Experimental
Non-appendiceal source
Control
Experimental
No. of
Patients Proportion with Composite Outcome
Days of Antibiotic
TherapySubgroup
0.10.0
7 (5–10)
5 (4–6)
4 (4–5)
8 (5–10)
8 (5–10)
4 (4–5)
8 (5–10)
4 (4–5)
8 (5–10)
4 (4–5)
8 (5–10)
4 (4–5)
8 (5–10)
11 (8–19)
11 (7–17)
4 (4–5)
189
211
71
47
120
122
94
102
86
86
174
171
34
39
226
218
median
(interquartile range)
The New England Journal of Medicine 
Downloaded from nejm.org at WASHINGTON UNIV SCH MED MEDICAL LIB on June 15, 2015. For personal use only. No other uses without permission. 
 Copyright © 2015 Massachusetts Medical Society. All rights reserved. 
n engl j med 372;21 nejm.org May 21, 20152004
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
tients in whom systemic antimicrobial agents are 
administered until after the resolution of signs 
and symptoms of sepsis.
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